Reliable and cost-effective serodiagnosis of rheumatoid arthritis
Abstract Early diagnosis of patients with rheumatoid arthritis (RA) optimises therapeutic benefit and the probability of achieving disease remission. Notwithstanding clinical acumen, early diagnosis is dependent on access to reliable serodiagnostic procedures, as well as on the discerning application and interpretation of these. In the case of RA, however, no disease-specific serodiagnostic procedure is available due to the multi-factorial and polygenic nature of this autoimmune disorder. This has resulted in the development of an array of serodiagnostic procedures based on the detection of autoantibodies reactive with various putative autoantigens. Other procedures based on measurement of elevations in the concentrations of systemic biomarkers of inflammation, most commonly acute phase reactants and cytokines/chemokines, are used as objective indices of disease activity. Following a brief overview of RA research in African populations, the current review is focused on those autoantibodies/biomarkers, specifically rheumatoid factor, anti-citrullinated peptide antibodies and C-reactive protein, which are currently recognised as being the most reliable and cost-effective with respect to disease prediction and diagnosis, as well as in monitoring activity and outcome..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Rheumatology international - 36(2016), 6 vom: 09. Feb., Seite 751-758 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meyer, Pieter W. A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-citrullinated peptide antibodies |
|---|
| Anmerkungen: |
© Springer-Verlag Berlin Heidelberg 2016 |
|---|
| doi: |
10.1007/s00296-016-3433-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2044921960 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2044921960 | ||
| 003 | DE-627 | ||
| 005 | 20230331101454.0 | ||
| 007 | tu | ||
| 008 | 200819s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-016-3433-3 |2 doi | |
| 035 | |a (DE-627)OLC2044921960 | ||
| 035 | |a (DE-He213)s00296-016-3433-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Meyer, Pieter W. A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reliable and cost-effective serodiagnosis of rheumatoid arthritis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag Berlin Heidelberg 2016 | ||
| 520 | |a Abstract Early diagnosis of patients with rheumatoid arthritis (RA) optimises therapeutic benefit and the probability of achieving disease remission. Notwithstanding clinical acumen, early diagnosis is dependent on access to reliable serodiagnostic procedures, as well as on the discerning application and interpretation of these. In the case of RA, however, no disease-specific serodiagnostic procedure is available due to the multi-factorial and polygenic nature of this autoimmune disorder. This has resulted in the development of an array of serodiagnostic procedures based on the detection of autoantibodies reactive with various putative autoantigens. Other procedures based on measurement of elevations in the concentrations of systemic biomarkers of inflammation, most commonly acute phase reactants and cytokines/chemokines, are used as objective indices of disease activity. Following a brief overview of RA research in African populations, the current review is focused on those autoantibodies/biomarkers, specifically rheumatoid factor, anti-citrullinated peptide antibodies and C-reactive protein, which are currently recognised as being the most reliable and cost-effective with respect to disease prediction and diagnosis, as well as in monitoring activity and outcome. | ||
| 650 | 4 | |a Anti-citrullinated peptide antibodies | |
| 650 | 4 | |a Autoantibodies | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a Inflammatory biomarkers | |
| 650 | 4 | |a Rheumatoid factor | |
| 700 | 1 | |a Ally, Mahmood M. T. M. |4 aut | |
| 700 | 1 | |a Anderson, Ronald |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 36(2016), 6 vom: 09. Feb., Seite 751-758 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2016 |g number:6 |g day:09 |g month:02 |g pages:751-758 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00296-016-3433-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2016 |e 6 |b 09 |c 02 |h 751-758 | ||